WO2008061236A3 - Sulfoximines as kinase inhibitors - Google Patents

Sulfoximines as kinase inhibitors Download PDF

Info

Publication number
WO2008061236A3
WO2008061236A3 PCT/US2007/084999 US2007084999W WO2008061236A3 WO 2008061236 A3 WO2008061236 A3 WO 2008061236A3 US 2007084999 W US2007084999 W US 2007084999W WO 2008061236 A3 WO2008061236 A3 WO 2008061236A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfoximines
kinase inhibitors
modulate
regulate
formula
Prior art date
Application number
PCT/US2007/084999
Other languages
French (fr)
Other versions
WO2008061236A2 (en
Inventor
Julie A Wurster
Eugene C Hull Iii
Richard D Yee
Sougato Boral
Thomas C Malone
Shimiao Wang
Original Assignee
Allergan Inc
Julie A Wurster
Eugene C Hull Iii
Richard D Yee
Sougato Boral
Thomas C Malone
Shimiao Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Julie A Wurster, Eugene C Hull Iii, Richard D Yee, Sougato Boral, Thomas C Malone, Shimiao Wang filed Critical Allergan Inc
Priority to JP2009537394A priority Critical patent/JP2010510242A/en
Priority to EP07864544.7A priority patent/EP2099757B1/en
Priority to BRPI0718895-1A priority patent/BRPI0718895A2/en
Priority to CA002669704A priority patent/CA2669704A1/en
Priority to AU2007319151A priority patent/AU2007319151B2/en
Publication of WO2008061236A2 publication Critical patent/WO2008061236A2/en
Publication of WO2008061236A3 publication Critical patent/WO2008061236A3/en
Priority to HK10102636.4A priority patent/HK1134674A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Formula (I)
PCT/US2007/084999 2006-11-16 2007-11-16 Sulfoximines as kinase inhibitors WO2008061236A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009537394A JP2010510242A (en) 2006-11-16 2007-11-16 Sulfoximine as a kinase inhibitor
EP07864544.7A EP2099757B1 (en) 2006-11-16 2007-11-16 Sulfoximines as kinase inhibitors
BRPI0718895-1A BRPI0718895A2 (en) 2006-11-16 2007-11-16 SULFOXIMIN COMPOUND AND USE OF SUCH COMPOUND
CA002669704A CA2669704A1 (en) 2006-11-16 2007-11-16 Sulfoximines as kinase inhibitors
AU2007319151A AU2007319151B2 (en) 2006-11-16 2007-11-16 Sulfoximines as kinase inhibitors
HK10102636.4A HK1134674A1 (en) 2006-11-16 2010-03-15 Sulfoximines as kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86608006P 2006-11-16 2006-11-16
US60/866,080 2006-11-16

Publications (2)

Publication Number Publication Date
WO2008061236A2 WO2008061236A2 (en) 2008-05-22
WO2008061236A3 true WO2008061236A3 (en) 2008-07-31

Family

ID=39284047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084999 WO2008061236A2 (en) 2006-11-16 2007-11-16 Sulfoximines as kinase inhibitors

Country Status (8)

Country Link
US (1) US7915443B2 (en)
EP (1) EP2099757B1 (en)
JP (1) JP2010510242A (en)
AU (1) AU2007319151B2 (en)
BR (1) BRPI0718895A2 (en)
CA (1) CA2669704A1 (en)
HK (1) HK1134674A1 (en)
WO (1) WO2008061236A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456476B2 (en) 2003-06-27 2008-11-25 Intel Corporation Nonplanar semiconductor device with partially or fully wrapped around gate electrode and methods of fabrication
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US7042009B2 (en) 2004-06-30 2006-05-09 Intel Corporation High mobility tri-gate devices and methods of fabrication
US20060086977A1 (en) 2004-10-25 2006-04-27 Uday Shah Nonplanar device with thinned lower body portion and method of fabrication
US7518196B2 (en) 2005-02-23 2009-04-14 Intel Corporation Field effect transistor with narrow bandgap source and drain regions and method of fabrication
US7858481B2 (en) 2005-06-15 2010-12-28 Intel Corporation Method for fabricating transistor with thinned channel
US7547637B2 (en) 2005-06-21 2009-06-16 Intel Corporation Methods for patterning a semiconductor film
US7279375B2 (en) * 2005-06-30 2007-10-09 Intel Corporation Block contact architectures for nanoscale channel transistors
US20070090416A1 (en) 2005-09-28 2007-04-26 Doyle Brian S CMOS devices with a single work function gate electrode and method of fabrication
US7485503B2 (en) 2005-11-30 2009-02-03 Intel Corporation Dielectric interface for group III-V semiconductor device
WO2007087419A2 (en) * 2006-01-24 2007-08-02 Allergan, Inc. Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer
US8143646B2 (en) 2006-08-02 2012-03-27 Intel Corporation Stacking fault and twin blocking barrier for integrating III-V on Si
US8143410B2 (en) * 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
US8558002B2 (en) * 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
US8642067B2 (en) * 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8362566B2 (en) 2008-06-23 2013-01-29 Intel Corporation Stress in trigate devices using complimentary gate fill materials
AR076332A1 (en) 2009-04-21 2011-06-01 Boehringer Ingelheim Int HETEROCICLIC DERIVATIVES OF 5-ALQUINIL-PIRIDINAS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USE OF THE SAME FOR THE TREATMENT AND / OR PREVENTION OF CANCER, INFLAMMATORY PROCESSES, AUTOIMMUNES, AND / OR INFECTIONS.
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
CN105814021B (en) * 2013-12-12 2020-03-13 阿勒根公司 Substituted nicotinamide derivatives as kinase inhibitors
RU2711749C2 (en) 2013-12-12 2020-01-21 Аллерган, Инк. Substituted dialkyl (oxide)-λ4-sulfanilidene nicotinamide derivatives as kinase inhibitors
CN111662227B (en) * 2019-03-06 2022-07-05 中国科学院上海药物研究所 O-aminopyridine alkyne compound and preparation method and application thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0023392A2 (en) * 1979-07-18 1981-02-04 Imperial Chemical Industries Plc Diphenyl ether compounds, and herbicidal compositions and processes utilising them
JPS5890555A (en) * 1982-11-22 1983-05-30 Ishihara Sangyo Kaisha Ltd Benzamide derivative and herbicide containing the same
EP0109575A2 (en) * 1982-11-04 1984-05-30 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Benzoic-acid derivatives, process and means for its production
JPH05294930A (en) * 1992-04-21 1993-11-09 Yoshitomi Pharmaceut Ind Ltd Stylyl compound
WO1998056757A1 (en) * 1997-06-11 1998-12-17 Sankyo Company, Limited Benzylamine derivatives
WO2000027823A1 (en) * 1998-11-09 2000-05-18 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
WO2002050071A1 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
JP2002205464A (en) * 2000-11-10 2002-07-23 Oji Paper Co Ltd Heat-sensitive recording medium
WO2004014300A2 (en) * 2002-08-09 2004-02-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2005037800A1 (en) * 2003-10-16 2005-04-28 Schering Aktiengesellschaft Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
WO2005108370A1 (en) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Benzene compounds
WO2006099974A1 (en) * 2005-03-23 2006-09-28 Bayer Schering Pharma Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2383874A (en) * 1941-04-24 1945-08-28 Swiss Firm Of J R Geigy A G p-aminobenzenesulphonamides and a process for their manufacture
GB602558A (en) * 1945-10-24 1948-05-28 Geigy Ag J R Manufacture of aromatic acyl-sulphonamides
DE821977C (en) * 1949-10-02 1951-11-22 Basf Ag Process for the production of azo dyes
ZA804076B (en) * 1979-07-18 1981-06-24 Ici Ltd Herbicides
GB2061914A (en) * 1979-11-01 1981-05-20 American Cyanamid Co Substituted anilines and their use as anti-atherosclerotic agents
JPS5998056A (en) * 1982-11-04 1984-06-06 エフ・ホフマン−ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト Herbocidal benzoic acid derivatives
JPS6216465A (en) * 1985-03-14 1987-01-24 Nissan Chem Ind Ltd Benzamide derivative, production thereof and soil blight controlling agent
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
JPH01502755A (en) * 1987-03-18 1989-09-21 アメリカン・ホーム・プロダクツ・コーポレイション Sulfonylcarboxamide
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
CA2078214C (en) 1990-04-02 1995-03-28 Robert Lee Dow Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2068355A1 (en) * 1991-05-14 1992-11-15 Mark S. Chambers Benzodiazephine derivatives, compositions containing them and their use in therapy
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
JP2600644B2 (en) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 Thiazolyl benzofuran derivative
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
BR9207175A (en) 1992-10-28 1995-12-12 Genentech Inc Composition containing vascular endothelial cell growth factor antagonist polypeptide monoclonal antibody amino acid sequence and method of treatment of tumor in mammal
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
DE4410453A1 (en) * 1994-03-25 1995-09-28 Hoechst Ag Substituted heterocyclic carboxylic acid amide esters, their preparation and their use as medicaments
KR970707098A (en) * 1994-10-27 1997-12-01 후지야마 아키라 Quinolines and fused N-heterocycles as bradykinin antagonists as pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists,
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU722514B2 (en) * 1995-12-28 2000-08-03 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
HUP0300406A3 (en) * 2000-03-22 2003-10-28 Bayer Cropscience Gmbh Heterocyclic acylsulfimides, a method for their production, compositions containing them and their use as pesticides
DE10021246A1 (en) * 2000-04-25 2001-10-31 Schering Ag New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis
US20020054093A1 (en) 2000-10-04 2002-05-09 Gonzalez Emmanuel C. Ergonomic graphic interface for webpages, internet browsers and computers
DE102004031323A1 (en) * 2004-06-29 2006-01-19 Bayer Cropscience Ag Substituted Pyridazincarboxamide and derivatives thereof
WO2006013449A1 (en) 2004-07-30 2006-02-09 Adriaan Francois Roberts A swimming pool installation and accessory
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
JP2008528663A (en) 2005-02-01 2008-07-31 アストラゼネカ アクチボラグ Pyrimidine compounds having Ties (TEK) inhibitory activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
JP5081807B2 (en) * 2005-03-16 2012-11-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Novel thiophenesulfoximines for the treatment of complement-mediated diseases and conditions
US20080194552A1 (en) * 2005-03-31 2008-08-14 Astrazeneca Ab Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
DK1973545T3 (en) 2005-12-23 2013-02-25 Ariad Pharma Inc Bicyclic heteroaryl compounds
DE102006041382A1 (en) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl sulfoximides as protein kinase inhibitors
TW200930369A (en) * 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0023392A2 (en) * 1979-07-18 1981-02-04 Imperial Chemical Industries Plc Diphenyl ether compounds, and herbicidal compositions and processes utilising them
EP0109575A2 (en) * 1982-11-04 1984-05-30 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Benzoic-acid derivatives, process and means for its production
JPS5890555A (en) * 1982-11-22 1983-05-30 Ishihara Sangyo Kaisha Ltd Benzamide derivative and herbicide containing the same
JPH05294930A (en) * 1992-04-21 1993-11-09 Yoshitomi Pharmaceut Ind Ltd Stylyl compound
WO1998056757A1 (en) * 1997-06-11 1998-12-17 Sankyo Company, Limited Benzylamine derivatives
WO2000027823A1 (en) * 1998-11-09 2000-05-18 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
JP2002205464A (en) * 2000-11-10 2002-07-23 Oji Paper Co Ltd Heat-sensitive recording medium
WO2002050071A1 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
WO2004014300A2 (en) * 2002-08-09 2004-02-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2005037800A1 (en) * 2003-10-16 2005-04-28 Schering Aktiengesellschaft Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
WO2005108370A1 (en) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Benzene compounds
WO2006099974A1 (en) * 2005-03-23 2006-09-28 Bayer Schering Pharma Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Interchim Intermediates", 9 July 2007, INTERCHIM 211 BIS AV J.F. KENNEDY BP 1140 MONTLUCON 03103 FRANCE *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "(Pyridyloxy)benzamide derivatives as herbicides", XP002477770, retrieved from STN Database accession no. 1983:522316 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ISHIHARA, SADAO ET AL: "Preparation of benzylamine derivatives having excellent ileal bile acid transporter inhibitory activity", XP002477766, retrieved from STN Database accession no. 1999:7963 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KONISHI, MITSUHIRO ET AL: "Preparation of styrenecarboxamides as leukotriene antagonists", XP002477769, retrieved from STN Database accession no. 1994:191363 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MATSUSAWA, SHIGEJI ET AL: "Heat-sensitive recording materials containing specific color-developing materials", XP002477768, retrieved from STN Database accession no. 2002:547198 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SUZUKI, NOBUYASU ET AL: "Preparation of benzene derivatives containing amide moiety as ACC inhibitors", XP002477767, retrieved from STN Database accession no. 2005:1216425 *
DATABASE CHEMCATS [online] CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002477771, retrieved from STN Database accession no. 2035822323 *

Also Published As

Publication number Publication date
AU2007319151A1 (en) 2008-05-22
WO2008061236A2 (en) 2008-05-22
JP2010510242A (en) 2010-04-02
EP2099757A2 (en) 2009-09-16
CA2669704A1 (en) 2008-05-22
US7915443B2 (en) 2011-03-29
US20090099181A1 (en) 2009-04-16
HK1134674A1 (en) 2010-05-07
AU2007319151B2 (en) 2013-05-23
EP2099757B1 (en) 2014-06-25
BRPI0718895A2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
WO2008061236A3 (en) Sulfoximines as kinase inhibitors
BR112012033658A2 (en) bipyridyl derivatives useful for the treatment of kinase-induced diseases
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2008054599A3 (en) Rho kinase inhibitors
WO2008002671A3 (en) Metalloprotease inhibitors
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
WO2007123892A3 (en) Raf inhibitors and their uses
WO2008021369A3 (en) Tricyclic compounds and its use as tyrosine kinase modulators
EA200870504A1 (en) CONNECTIONS AND COMPOSITIONS AS HEDGEHOG MODULATORS
WO2010006086A3 (en) Kinase inhibitors and methods of use
EA201071089A1 (en) HINAZOLIN DERIVATIVES AS RAF-KINASE MODULATORS AND METHODS FOR THEIR APPLICATION
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
EA201490922A1 (en) HIDANTOIN DERIVATIVES USEFUL AS KV3-CHANNEL INHIBITORS
MX2009011951A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2007105058A8 (en) Pyrazole compounds
WO2008080001A3 (en) Compounds and methods for kinase modulation, and indications therefor
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
WO2007125103A3 (en) Benzamide glucokinase activators
WO2007081755A3 (en) Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
WO2006076442A3 (en) Triazolopyrimidine derivatives
WO2012058645A8 (en) Heterocyclic tyrosine kinase inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2011090738A3 (en) Type ii raf kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07864544

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2669704

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009537394

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007319151

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007864544

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007319151

Country of ref document: AU

Date of ref document: 20071116

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0718895

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090518